145 related articles for article (PubMed ID: 36409821)
1. The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
Llano E; Todeschini AL; Felipe-Medina N; Corte-Torres MD; Condezo YB; Sanchez-Martin M; López-Tamargo S; Astudillo A; Puente XS; Pendas AM; Veitia RA
Cancer Res; 2023 Jan; 83(2):239-250. PubMed ID: 36409821
[TBL] [Abstract][Full Text] [Related]
2. Detection of FOXL2 C134W Mutation Status by a Novel BaseScope In Situ Hybridization Assay is Highly Sensitive and Specific for Adult Granulosa Cell Tumors.
Hammer PM; Wang A; Beard C; Zdravkovic S; Tenney T; Liang B; Das I; Bremer R; Wang LC; McCluggage WG; Stewart CJR; Howitt BE
Mod Pathol; 2023 Nov; 36(11):100318. PubMed ID: 37634867
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 mitigates the SMAD3/FOXL2
Secchi C; Benaglio P; Mulas F; Belli M; Stupack D; Shimasaki S
J Transl Med; 2021 Feb; 19(1):90. PubMed ID: 33639972
[TBL] [Abstract][Full Text] [Related]
4. The FOXL2 mutation (c.402C>G) in adult-type ovarian granulosa cell tumors of three Japanese patients: clinical report and review of the literature.
Takahashi A; Kimura F; Yamanaka A; Takebayashi A; Kita N; Takahashi K; Murakami T
Tohoku J Exp Med; 2013 Dec; 231(4):243-50. PubMed ID: 24257635
[TBL] [Abstract][Full Text] [Related]
5. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.
Pilsworth JA; Cochrane DR; Neilson SJ; Moussavi BH; Lai D; Munzur AD; Senz J; Wang YK; Zareian S; Bashashati A; Wong A; Keul J; Staebler A; van Meurs HS; Horlings HM; Kommoss S; Kommoss F; Oliva E; Färkkilä AE; Gilks B; Huntsman DG
J Pathol Clin Res; 2021 May; 7(3):243-252. PubMed ID: 33428330
[TBL] [Abstract][Full Text] [Related]
6. The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
Carles A; Trigo-Gonzalez G; Cao Q; Cheng SG; Moksa M; Bilenky M; Huntsman DG; Morin GB; Hirst M
Cancer Res; 2020 Sep; 80(17):3480-3491. PubMed ID: 32641414
[TBL] [Abstract][Full Text] [Related]
7. Mutant FOXL2
Weis-Banke SE; Lerdrup M; Kleine-Kohlbrecher D; Mohammad F; Sidoli S; Jensen ON; Yanase T; Nakamura T; Iwase A; Stylianou A; Abu-Rustum NR; Aghajanian C; Soslow R; Da Cruz Paula A; Koche RP; Weigelt B; Christensen J; Helin K; Cloos PAC
Cancer Res; 2020 Sep; 80(17):3466-3479. PubMed ID: 32641411
[TBL] [Abstract][Full Text] [Related]
8. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary.
Jamieson S; Butzow R; Andersson N; Alexiadis M; Unkila-Kallio L; Heikinheimo M; Fuller PJ; Anttonen M
Mod Pathol; 2010 Nov; 23(11):1477-85. PubMed ID: 20693978
[TBL] [Abstract][Full Text] [Related]
9. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.
Fleming NI; Knower KC; Lazarus KA; Fuller PJ; Simpson ER; Clyne CD
PLoS One; 2010 Dec; 5(12):e14389. PubMed ID: 21188138
[TBL] [Abstract][Full Text] [Related]
10. FOXL2 in adult-type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?
Pilsworth JA; Todeschini AL; Neilson SJ; Cochrane DR; Lai D; Anttonen M; Heikinheimo M; Huntsman DG; Veitia RA
J Pathol; 2021 Nov; 255(3):225-231. PubMed ID: 34338304
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by increasing GnRH receptor expression in human granulosa cell tumors.
Cheng JC; Klausen C; Leung PC
PLoS One; 2013; 8(1):e55099. PubMed ID: 23372819
[TBL] [Abstract][Full Text] [Related]
12. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract][Full Text] [Related]
13. Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts.
Siegmund S; Sholl LM; Cornejo KM; Sangoi AR; Otis CN; Mehra R; Hirsch MS; Acosta AM
Mod Pathol; 2022 May; 35(5):697-704. PubMed ID: 34845303
[TBL] [Abstract][Full Text] [Related]
14. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W).
Kim JH; Yoon S; Park M; Park HO; Ko JJ; Lee K; Bae J
Oncogene; 2011 Apr; 30(14):1653-63. PubMed ID: 21119601
[TBL] [Abstract][Full Text] [Related]
15. Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.
Yanagida S; Anglesio MS; Nazeran TM; Lum A; Inoue M; Iida Y; Takano H; Nikaido T; Okamoto A; Huntsman DG
PLoS One; 2017; 12(6):e0178989. PubMed ID: 28594898
[TBL] [Abstract][Full Text] [Related]
16. Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations.
Croce S; de Kock L; Boshari T; Hostein I; Velasco V; Foulkes WD; McCluggage WG
Int J Gynecol Pathol; 2016 Jul; 35(4):301-8. PubMed ID: 26598979
[TBL] [Abstract][Full Text] [Related]
17. FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor.
Färkkilä A; McConechy MK; Yang W; Talhouk A; Ng Y; Lum A; Morin RD; Bushell K; Riska A; McAlpine JN; Gilks CB; Unkila-Kallio L; Anttonen M; Huntsman DG
J Mol Diagn; 2017 Jan; 19(1):126-136. PubMed ID: 27810330
[TBL] [Abstract][Full Text] [Related]
18. FOXL2
Fuller PJ; Nguyen T; Alexiadis M; Chu S
J Pathol; 2022 Jan; 256(1):1-3. PubMed ID: 34687235
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary.
Da Cruz Paula A; da Silva EM; Segura SE; Pareja F; Bi R; Selenica P; Kim SH; Ferrando L; Vahdatinia M; Soslow RA; Vidal A; Gatius S; Przybycin CG; Abu-Rustum NR; Matias-Guiu X; Rubin BP; Reis-Filho JS; DeLair DF; Weigelt B
Mod Pathol; 2020 Aug; 33(8):1606-1617. PubMed ID: 32203090
[TBL] [Abstract][Full Text] [Related]
20. Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted
Alexiadis M; Rowley SM; Chu S; Leung DTH; Stewart CJR; Amarasinghe KC; Campbell IG; Fuller PJ
Mol Cancer Res; 2019 Jan; 17(1):177-185. PubMed ID: 30166312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
